Free Trial
CVE:KNE

Kane Biotech 8/29/2023 Earnings Report

Kane Biotech logo
C$0.04 0.00 (0.00%)
As of 08/8/2025 03:28 PM Eastern

Kane Biotech EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Kane Biotech Revenue Results

Actual Revenue
$0.66 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kane Biotech Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kane Biotech Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Kane Biotech to Present at Advanced Wound Care Summit USA
Kane Biotech to Present at Advanced Wound Care Summit USA
See More Kane Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kane Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kane Biotech and other key companies, straight to your email.

About Kane Biotech

Kane Biotech (CVE:KNE), a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

View Kane Biotech Profile

More Earnings Resources from MarketBeat